Navigation Links
Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
Date:1/28/2009

MONTVALE, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) today announced that, following a review of its clinical development portfolio and its current financial status, the Board of Directors and management have determined that it is in the best interest of the Company to focus its resources on maximizing the value of its diagnostic assets and to terminate all ongoing clinical trials of its product candidates alagebrium and SYI-2074, including the following:

- the BENEFICIAL study, which was a Phase 2 double-blind, placebo-controlled, randomized trial of alagebrium in patients with chronic systolic heart failure;

- the BREAK study, which was a Phase 2 double-blind, placebo-controlled, randomized trial of alagebrium in patients with diastolic heart failure; and

- the Phase 2 trial of a topical formulation of SYI-2074 for the treatment of chronic, mild-to-moderate plaque psoriasis in adults.

Each of these trials will be terminated as promptly as possible.

As noted previously, the Company has submitted an application for 510(k) clearance for its HAPTOCHEK(TM) diagnostic test kit, a protein-based clinical laboratory test to identify patients with Hp2-2 diabetes. The 90-day review process of such submission is ongoing, during which time the FDA will determine whether the kit can be distributed to labs throughout the country as an in vitro diagnostic.

The Company is continuing to explore strategic alternatives in order to monetize its technology assets, which may take the form of sales or licensing transactions with respect to those assets. In light of the Company's cash position and current negative economic and capital markets conditions, if the Company is unable to enter into such transactions in a timely manner, the Company's ability to continue operations beyond the second quarter of 2009 is in do
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
3. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
4. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
5. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
6. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
7. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
8. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
9. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
10. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 Magnaquest, a leading ... and cloud computing operators has signed a Proof ... for Internet of Things (IoT) related initiative. The ... subscription model.      (Logo: http://photos.prnewswire.com/prnh/20140807/700645 ... for business innovations to make healthcare services more ...
(Date:7/30/2015)... 2015  ResMed (NYSE: RMD ) ... agreement to acquire Curative Medical, a privately-held ... breathing medical devices and accessories. ... leadership in sleep and respiratory medicine, will ... suffering from sleep-disordered breathing and ...
(Date:7/30/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® and t:flex™ Insulin Pumps, today ... Agreements with Dexcom, Inc. to allow the integration ... Dexcom G5 and G6 continuous glucose monitoring ("CGM") ... platform with Dexcom,s future CGM systems is an ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... ALBUQUERQUE, N.M., Jan. 25, 2011 Exagen Diagnostics, ... and markets proprietary tests, announced today the completion of ... New Mexico Science and Technology Park . The expansion, ... laboratory, allows Exagen to accommodate growing test volume for ...
... Mass., Jan. 25, 2011 Generex Biotechnology Corporation ( ... together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, ... amended the Clinical Study Agreement with The Henry M. ... ( www.hjf.org ) in regard to the on-going Phase ...
Cached Medicine Technology:Exagen's Corporate Expansion Creates Job Opportunities in New Mexico 2Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study 2Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study 3Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study 4Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study 5
(Date:7/31/2015)... PA (PRWEB) , ... July 31, 2015 , ... M3 ... is excited to launch three new Board Exam Courses. , The additions of ... Doc Board Exam Prep from MDLinx makes preparing for the exam easy and painless. ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... According ... and cosmetic experts gathered to see if they could reach a consensus on the ... breast augmentation and facelifts. Overall, the group reached 90 percent consensus on a series ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... and potential patients alike on various plastic surgery procedures including, but not limited ... such popular dermatology procedures like Botox and fillers. , Staying up to ...
(Date:7/31/2015)... ... July 31, 2015 , ... Transfinder, a software company based ... sales were up 16 percent year-over-year for the first six months ended June 30, ... he expected Transfinder to beat last year’s record-revenue mark of $10.4 million. , “We ...
(Date:7/31/2015)... ... , ... Girl Scouts of Historic Georgia and Peach State Health Plan are ... a Friend First" program. Representatives from Peach State Health Plan presented a $10,000 check ... and our parent company, Centene Corporation, are dedicated to raising anti-bullying awareness. We are ...
Breaking Medicine News(10 mins):Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2
... to be Opened in the North West of England -, ... ORCH ), a leading worldwide provider of identity DNA testing,services, ... in the North West of England later this year following ... work was awarded to Orchid,Cellmark following the North West/South West ...
... April 21 MedCath Corporation,(Nasdaq: MDTH ) announced ... 2008, which ended March 31, 2008. In addition, MedCath,announced ... second quarter of fiscal 2008 and its revised outlook ... asset held for sale. MedCath,announced on March 24, 2008 ...
... HILL, N.C., April 21 Marketing brand leaders ... services offered by,Best Practices, LLC and in particular ... the Best Practice Database (, http://www.BestPracticeDatabase.com ). ... downloaded individually, many commercial leaders have come to,find ...
... planting low-allergen species, avoiding high pollen hours can help ... with allergies, it can be difficult to enjoy their ... the misery of sneezing, itchy eyes, congestion and, in ... times of high pollen counts puts patients at risk ...
... Association (PCMA) issued the following statement today,regarding a story ... "The New York Times has missed another opportunity to ... In the April 14,2008 piece, ,Co-payments Soar for Drugs ... for the high cost of biotech treatments. Then,in a ...
... The American Academy of,Pediatrics (AAP) highlights the ... Immunization Week, April 19-26. Vaccines,have eliminated or reduced ... a critical component of the nation,s public health ... Disease Control and Prevention,before immunization:, -- Over ...
Cached Medicine News:Health News:Orchid Cellmark to Open a New Forensic Facility in the United Kingdom to Meet Increasing Demand for Its Services 2Health News:Orchid Cellmark to Open a New Forensic Facility in the United Kingdom to Meet Increasing Demand for Its Services 3Health News:Orchid Cellmark to Open a New Forensic Facility in the United Kingdom to Meet Increasing Demand for Its Services 4Health News:MedCath Provides Preliminary Second Quarter Fiscal 2008 Earnings and Updates Fiscal 2008 Outlook 2Health News:MedCath Provides Preliminary Second Quarter Fiscal 2008 Earnings and Updates Fiscal 2008 Outlook 3Health News:MedCath Provides Preliminary Second Quarter Fiscal 2008 Earnings and Updates Fiscal 2008 Outlook 4Health News:MedCath Provides Preliminary Second Quarter Fiscal 2008 Earnings and Updates Fiscal 2008 Outlook 5Health News:MedCath Provides Preliminary Second Quarter Fiscal 2008 Earnings and Updates Fiscal 2008 Outlook 6Health News:MedCath Provides Preliminary Second Quarter Fiscal 2008 Earnings and Updates Fiscal 2008 Outlook 7Health News:Best Practice Database Provides Exceptional Value to Marketing Executives 2Health News:Allergies Can Dig Into Gardening's Fun 2Health News:PCMA Response to New York Times Article on Biotech Medicine Costs 2Health News:AAP Encourages Parents to Immunize Their Children 2
... This upright freezer uses ultra-thin vacuum ... traditional urethane insulation, to increase storage ... Holds (336) 2" boxes or 3,336 ... preservation, reduces energy consumption and extends ...
... Simple, economical, moderate-sized CO2 incubator with ... with glass inner door, HEPA filtered ... minimize sample exposure. Simple, large character ... IR CO2 sensing and mulitple temperature ...
... By combining the corrosion resistance ... antibacterial properties of copper, SANYO offers ... sterile, long-lasting and maintenance-free. The sterile ... valid test results and the safety ...
ArcticTemp Upright Freezer -20C. Quick, even freezing. Heavy duty compressor. Deep door racks. Front gated bottom shelf. Interior light. Locks One year warranty on unit and 5 year warranty on compres...
Medicine Products: